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Abstract
Background: Female Sex workers (FSW) are important in driving HIV transmission in West Africa. The Yerelon clinic in
Burkina Faso has provided combined preventative and therapeutic services, including anti-retroviral therapy (ART), for FSWs
since 1998, with evidence suggesting it has decreased HIV prevalence and incidence in this group. No data exists on the
costs of such a combined prevention and treatment intervention for FSW. This study aims to determine the mean cost of
service provision per patient year for FSWs attending the Yerelon clinic, and identifies differences in costs between patient
groups.
Methods: Field-based retrospective cost analyses were undertaken using top-down and bottom-up costing approaches for
2010. Expenditure and service utilisation data was collated from primary sources. Patients were divided into groups
according to full-time or occasional sex-work, HIV status and ART duration. Patient specific service use data was extracted.
Costs were converted to 2012 US$. Sensitivity analyses considered removal of all research costs, different discount rates and
use of different ART treatment regimens and follow-up schedules.
Results: Using the top-down costing approach, the mean annual cost of service provision for FSWs on or off ART was
US$1098 and US$882, respectively. The cost for FSWs on ART reduced by 29%, to US$781, if all research-related costs were
removed and national ART monitoring guidelines were followed. The bottom-up patient-level costing showed the cost of
the service varied greatly across patient groups (US$505–US$1117), primarily due to large differences in the costs of different
ART regimens. HIV-negative women had the lowest annual cost at US$505.
Conclusion: Whilst FSWs may require specialised services to optimise their care and hence, the public health benefits, our
study shows that the cost of ART provision within a combined prevention and treatment intervention setting is comparable
to providing ART to other population groups in Africa.
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Introduction
In 2011 there were 34 million people living with HIV/AIDS,
with approximately two thirds in Sub-Saharan Africa [1] Anti-
Retroviral Treatment (ART) has long been recognised as the
mainstay therapy for HIV infected individuals, resulting in
decreased mortality rates and increased life expectancy. HAART
has also recently been shown to dramatically reduce the risk of
HIV acquisition amongst HIV discordant couples [2–4], sparking
heated debate regarding its use as a prevention strategy to reduce
HIV transmission rates, including amongst high-risk groups such
as Female Sex Workers (FSW) [5–7]. Early diagnosis and
treatment of these individuals would not only benefit them but
could also reduce HIV transmission to their clients and general
population [2]. This could be especially important in concentrated
epidemic settings, as seen in West Africa, where FSW are thought
to drive HIV transmission [8–11].
This central role of FSW in HIV transmission has led to the
development of numerous targeted prevention programmes,
which can result in large reductions in risk behaviour and HIV
prevalence amongst participants [12,13]. The cost-effectiveness of
these interventions in middle income countries has already been
shown [14–18] However, there is limited data on interventions
offering combined HIV prevention and treatment services for
FSW, with evidence suggesting this marginalised group may
currently be underserved [19,20].
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In Burkina Faso, the HIV prevalence amongst the general
population was 1.2% in 2009 [21], and between 7.7% and 36.2%
[22] amongst FSW depending on region. The Centre Muraz, a
bio-medical research centre in Bobo-Dioulasso, initiated the
Yerelon (‘‘know yourself’’ in vernacular language) research project
in 1998 to develop and test a programme of combined prevention
and treatment services for FSW, including ART provision [23]
The clinic is sponsored and funded by Agence Nationale de
Recherche sur le Sida. (ANRS).
With this current widespread financial crisis, economic evalu-
ations have become crucial in guiding priority setting. To date,
there is no cost data available on the provision of ART to FSW.
Through the collection of resource use and cost data, we aimed to
estimate the overall and per patient yearly cost of providing
services to FSW attending the Yerelon project. We also
investigated how costs varied between different occupational
exposure categories or by ART duration.
Methods
Study Setting
The Yerelon project relies on peer educators to recruit, educate
and ensure high follow-up rates of FSW. It is a specialised clinic
that provides condoms, STI testing/treatment, HIV testing and
counselling, ART, medical consultations and safer sex counselling
and psychological support. Peer-educators are crucial to the
clinic’s success as they identify FSW in the ‘milieu’, get them tested
and treated at the clinic and retain them in care. They also
conduct daily group education sessions with women in the waiting
room. Both a pharmacy and laboratory are on site and all services
are free of charge to participants.
The clinic offers a number of different visit types. As part of the
research cohort, FSW are encouraged to attend the clinic every
three months for a full medical visit (type ‘‘V’’), which includes
completion of a behavioural questionnaire, and meeting both a
psychologist to discuss treatment or diagnosis issues and a doctor
for a full medical examination with genital examination. The
patients then undergo blood tests and microscopic examination of
vaginal swabs in the laboratory, and conclude their visit at the
pharmacy where a nurse dispenses any required medications.
FSW also attend scheduled treatment adherence visits (type ‘‘T’’)
at different time intervals to receive ART medications and
adherence support by a trained psychologist as required. Lastly,
they can visit the clinic at any time if they are unwell to receive
medical support based on their need (type ‘‘I’’). Visits ‘‘T’’ and ‘‘I’’
generally do not require the psychologist, investigator or
laboratory technician and are solely for medical reviews or ART
dispensing. Both HIV positive and negative women follow the
same clinical follow-up schedule, differing only in the laboratory
investigations undertaken (Table 1).
Since 1998, the project has enrolled 917 women with evidence
suggesting HIV incidence has reduced over this period [23].
Recently, the project has also demonstrated high adherence to
ART in this marginalised group, with long-term virological and
immunological responses being comparable to those in the general
population [23–25].
Data collection
We collected cost and output data retrospectively from the
Yerelon clinic in Bobo-Dioulasso, for the 12-month period from
January to December 2010. Financial and economic costs were
collected from the provider perspective and classified as capital or
recurrent [26]. Separate start-up costs were not included as they
preceded our study by 12 years and documentation was not
available. They were deemed negligible by the principal investi-
gator Recurrent inputs included personnel, supplies and building
operation and maintenance, while capital costs included building
space, training and equipment. Capital costs were depreciated
using the Burkina Faso Central Bank discount rate of 4.25%
[26,27]. The life span of equipment was estimated from the
German Government Technical Agency [28] and by interviewing
staff.
Data on patient numbers and total visits were extracted from
the project’s database. Pricing information was gathered from
pharmacy and equipment catalogues and project accounts. Prices
for anti-retroviral drugs were estimated using clinic receipts. All
costs were collected in West African Francs (CFA), inflated to 2012
prices where appropriate (CPI 2.8%) [29], and converted to US$
using the 2012 average exchange rate (1US$= 499.51 CFA) [30].
Firstly, a top-down approach [31] was used to calculate the total
annual cost of running the clinic. Top-down costs included all
costs required to deliver health services within the Yerelon clinic,
and were estimated from clinic administrative records. Data on
consumption of consumables such as small laboratory items
including reagents, slides and swabs was not available. Thus,
receipts of consumable purchases during the study period were
used. All anti-retroviral drugs and female condoms were donated
Table 1. Comparison of follow-up schedule in National guidelines and at the Yerelon clinic.
Time Vo D15 M1 M3 M6 M9 M12
Clinical exam N P B P NPB NPB NPB N P PB
Psychology N P N P N P N P N P N P
Questionnaire N P N P N P N P N P N P
HIV Serology N PB N N N N N
Vaginal swab N PB N P N P N P N P N P
Syphilis* N PB
CD4 count N PB P P PB P PB
Viral load N P PB PB
bHCG** N P N P N P N P N P N P
P=HIV Positive women; N=HIV Negative women; B =National guidelines;
*VDRL test is used;
**Urinary pregnancy test; VO = First visit; D = day following enrolment; and M=month following enrolment.
doi:10.1371/journal.pone.0100107.t001
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goods and were consequently considered as economic costs and
were priced according to central pharmacy price lists. Adminis-
tration costs charged to the Yerelon project by Centre Muraz were
10% of the clinic’s budget and were included in building operation
costs. Centre Muraz laboratory undertook all haematology and
biochemistry investigations, and itemised bills to the Yerelon
project were used to estimate costs.
Secondly, to estimate the costs of treating different patient types,
we adopted a combined bottom-up (patient-level) and top-down
approach [31]. We used an ingredients-based approach to
estimate the cost per client, based on observed resource use. Staff
time allocation was estimated per visit type (V, I, T) through staff
interviews. Data on frequency of visits and consumption of drugs,
supplies and lab tests were collected from individual patient
records and clinic stock records. All patient details were
anonymized and de-identified prior to analysis. The Ethics
Committee at the London School of Hygiene and Tropical
Medicine approved the study.
Cost analysis
For the top-down analysis, we separated patients into ART and
non-ART groups, with ART costs only being applied to the
women on ART but all other costs being apportioned evenly
across all women. We then calculated the mean annual cost per
woman treated in each group, and mean cost per visit as the main
output measures. This costing methodology is likely to underes-
timate the difference in cost between women on and off ART with
the costs per women on ART likely to be higher than our estimate.
However, it gives good estimates of total annual cost of the project
and proportion of costs for each cost category.
For the combined top-down/bottom-up analysis, we used
information from the project database to categorise women into
six groups to explore differences in costs between occupational
exposures and ART duration. The groups were: 1) Full-time sex
workers (FTSW) and 2) Occasional sex workers (OSW), both on
ART; 3) HIV Negative women; 4) Women in pre-ART care; 5)
Women commenced on ART in the last year; and 6) Women on
long-term ART (started ART in or before 2006).
A sample of 40 women was then randomly selected [32] from
facility records, with 10 selected from groups 1 and 2, and 5
selected from each other group. Unit prices were applied to all
direct resources used by each patient over the relevant time period.
The total cost of direct staff time for each type of visit (V, I, or T)
was calculated and applied accordingly to each analysed visit. The
cost of staff with no patient contact (such as security personnel) was
divided equally across all visits. Indirect and overhead costs, such
as rent and electricity, were estimated per patient visit using a top-
down approach, and were added to direct patient costs to produce
an estimated average cost of treating a woman from each group.
All 30 sampled women on ART (groups 1, 2, 5 and 6) were then
combined to obtain an average bottom-up cost estimate for
treating one woman on ART. The data was also reanalyzed using
the overlap between groups of occupational exposure and length
of treatment to increase sample size.
As the only mutually exclusive groups were HIV negative, HIV
positive on ART and HIV positive not on ART, the total annual
cost of running the clinic was estimated by multiplying the average
cost per woman in each of these groups by the total number of
women in that group in 2010.
Sensitivity analysis
A one-way sensitivity analysis was performed on the top-down
estimated mean cost per woman on ART, exploring the effects of
different discount rates (1%, 3% and 10%); changing all stavudine-
containing (dT4) regimens to ones containing zidovudine (AZT) or
tenofovir (TDF); basing the laboratory follow-up schedule on
National Guidelines and reducing consumable costs by 10% or
20%. Further sensitivity analyses considered removing all
research-related costs such as additional visits, laboratory inves-
tigations and staff used for research purposes and using minimum
staff and equipment required to operate the clinic for therapeutic
purposes alone. The high staff wages were also replaced with
public sector wages [33] to approximate a national therapeutic
setting. Lastly, a ‘Best Case Scenario’ was developed where
research costs were removed and National follow-up Guidelines
with public system wages were used.
Results
Total outputs
In total, 305 women attended the clinic in 2010, of which 187
women were on ART by December 2010. Of these women on
ART, 29 commenced treatment during the study period. The total
number of visits was 3027. A total of 40 patient records (13% of all
patients), detailing 449 visits (15% of all patient visits) were
analysed. Of the 30 sampled women on ART, 10 were on
Zidovudine/Lamivudine/Efavirenz (AZT/3TC/EFV). Three of
the women were on second line therapy Abacavir/Lamivudine/
Lopinavir/ritonavir (ABC/3TC/LPV/r) and one was on alterna-
tive therapy for HIV-2 Zidovudine/Lamivudine/Idinavir/Rito-
navir (3TC/AZT/IDV/RTV). The remaining women sampled
were either on Triomune (3TC/d4T+nevirapine (NVP)). or
AvocombH (3TC/AZT/)+NVP.
Total Annual Cost
The total annual financial cost of running the clinic was US$
261,140 (Table 2). The economic cost was US$ 309,165,
representing the additional value of donated buildings and ARVs.
Personnel costs accounted for the biggest proportion (36.4% or
US$ 112,621) of economic costs, followed by building operations
(17%) and laboratory costs (16%). ARVs only accounted for 13%
of total costs (US$ 40,500).
Unit Costs
The average economic cost across the overall cohort (ART or
no-ART) was US$1,014 per patient year and US$104 per visit.
This increased to US$1,098 per patient year (US$111 per visit) for
individuals on ART, and decreased to US$882 per patient year
(US$89 per visit) if not on ART.
Using the bottom-up approach, the average cost of a woman on
ART was US$913 per patient year. When looking across different
patient groups, the average annual cost of treating women on
established ART therapy was the highest at US$1,117. Despite the
more frequent visit schedule, the average cost of treating women
just initiating ART was a third less (US$734 per year – Table 3)
because of the cheaper first-line drugs used. Care for HIV negative
women or those in the pre-ART group incurred the lowest annual
cost at US$505 and US$545, respectively. As well as not being on
ART these women also attended 68% fewer visits, thus incurring
less cost.
Treatment costs for OSWs were higher than those for FTSWs
because two OSW were on more expensive anti-retroviral
therapies (second-line therapy or AZT/3TC/IDV/RTV), where-
as one FTSW died and two others dropped out of the programme
for 5–7 months. The cost per visit across patient groups ranged
from US$57 to US$99 depending on staff time encountered,
laboratory tests performed and whether ARTs were given. Using
the overlap between groups increased sample sizes by 10%
Cost of Providing ART for Female Sex Workers
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(FTSW) to 160% (OSW), but had little effect on the results
obtained.
A major proportion of costs across all groups were overhead
costs of US$356 for each patient, of which US$55 were non-direct
staff costs. ART costs differed greatly between patients, depending
on the regimen being taken. Second-line therapy (ABC/3TC/
LPV/r) was three times more expensive (US$1356 per patient
year) than the most commonly prescribed first-line regimen AZT/
3TC/EFV (US$394 per patient year). The total costs of non-ART
medication were low across all patient groups (12%–17% of total
cost). Laboratory costs were stable across all patient groups, except
amongst the HIV-negative women who had HIV serology testing
but no viral load and CD4 cell count tests.
When using the bottom-up or patient-specific data, the total
annual cost of the program was estimated to be US$ 237,378, 23%
less than the top-down approach. Discrepancies included total
ART costs being 58% higher in the bottom-up calculations and
personnel costs being 72% less than top-down estimates. These
variations were also evident in the breakdown of the unit costs
(Table 3). In the bottom-up approach, staff time was generally
allocated according to patient contact time, but did not account
for staff down time, or other staff activities such as monitoring and
evaluation, resulting in only 55% of total staff time being allocated
in the bottom-up approach. Laboratory costs were also estimated
to be 23% lower than the top-down estimates.
Sensitivity Analysis
All sensitivity analyses (Table 4) were performed on the top-
down cost estimates per patient year on ART. Firstly, varying the
discount rates (1%, 3% or 10%) had very little effect (,1%), as did
decreasing consumption of consumables (by 10% or 20%).
Similarly, switching all patients on d4T regimens to AZT
regimens, as per WHO guidelines [34], also had a small effect
(,1%), whereas changing d4T to TDF increased the average cost
by 12% (US$1,236). Changing AZT/3TC/NVP or EFV to TDF
containing regimens, to decrease toxicity and improve outcomes
[35], increased total ART costs for the clinic by 42% and the unit
cost of a person on ART to US$1,407 per year. We also estimated
the cost of increased capacity to include treatment of 500
additional women while assuming the same proportions of women
on and off ART. This decreased the treatment costs to US$859
per year for women on ART and US$643 for those not on ART.
When laboratory investigations and visits were restricted to
those recommended in the National Guidelines, the mean cost per
patient year on ART reduced to US$1,029 (6% reduction). It also
fell to US$1,040 if staff salaries were adjusted to public health
sector levels. If we adjusted both staff salaries and reduced the
number of staff to what would be needed if no research was
undertaken, personnel costs reduced by 59%. The mean cost per
patient-year on ART was US$928 when all research costs
including behavioural survey visits, extra laboratory tests, clinical
visits, staff and equipment necessary for these activities were
excluded. In our best case scenario, when all research costs as
above were excluded and remaining staff salaries were reduced to
public sector levels, the mean cost per patient on ART was
US$781 (29% reduction) per year.
Discussion
The cost-effectiveness of HIV prevention programmes aimed at
FSW has already been established [14–16], as has the cost-
effectiveness of providing HAART to HIV infected individuals in
resource poor settings [36,37]. However, little is known about the
cost of providing a combined intervention package, including
peer-based HIV and STI prevention, counseling and ART to
FSW in the same setting. Our study provides the first compre-
hensive costing of such an intervention- the Yerelon clinic in
Burkina Faso. We found that the average annual cost for an HIV-
positive FSW on ART, including research costs, was US$1,098,
whereas it was US$882 for a FSW not on ART.
A large proportion of costs were attributable to personnel (36%)
because the project employed 8 clinical staff and 17 support staff
with higher wages than their counterparts in the public system.
Laboratory costs exceeded ART costs because of elevated research
laboratory costs and the high proportion of women on cheaper
d4T containing therapy. The cost for non-ART medications was
exceptionally low (3.5% of total); reflecting the low unit cost of
generic medicines prescribed in this outpatient setting.
Analysis of bottom-up costs revealed that the difference in ART
regimens was the main driver of difference in costs between
groups. The average yearly cost of ART between groups ranged
from US$121 amongst women recently commenced on ART up to
US$515 amongst women on long established therapy. This latter
group was found to have the highest overall annual cost because
three women were on expensive ARV regimens costing more than
US$1,356 per year. In HIV negative women, the cost of care
Table 2. Top-down estimated financial and economic costs of running the clinic in 2010 (in 2012 US$).
Cost Category Financial US$ Total % Economic US$ Total %
Capital 9,025 3.5 20,611 6.7
Operations 53,592 20.9 53,779 17.4
Personnel 112,621 43.9 112,621 36.4
Transport 8,006 3.1 8,006 2.6
Medications 8,105 3.2 8,105 2.6
Consumables 12,465 4.9 12,465 4.0
Condoms 1,174 0.5 1612 0.5
Laboratory 49,968 19.5 49,968 16.2
Prophylaxis 1,499 0.6 1,499 0.5
ART 40,500 13.1
Total 256,454 100 309,165 100
doi:10.1371/journal.pone.0100107.t002
Cost of Providing ART for Female Sex Workers
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e100107
T
a
b
le
3
.
A
ve
ra
g
e
ca
te
g
o
ry
co
st
in
e
ac
h
p
at
ie
n
t
g
ro
u
p
an
d
fo
r
o
ve
ra
ll
b
o
tt
o
m
-u
p
an
d
to
p
-d
o
w
n
co
st
in
g
.
P
a
ti
e
n
t
su
b
-g
ro
u
p
C
o
st
C
a
te
g
o
ry
H
IV
-n
e
g
a
ti
v
e
H
IV
-p
o
si
ti
v
e
n
o
t
o
n
A
R
T
S
ta
rt
e
d
A
R
T
in
2
0
1
0
E
st
a
b
li
sh
e
d
A
R
T
F
T
S
W
o
n
A
R
T
O
S
W
o
n
A
R
T
B
o
tt
o
m
-u
p
o
n
A
R
T
T
o
p
-
d
o
w
n
o
n
A
R
T
P
e
rs
o
n
n
e
l
D
ir
ec
t
4
7
.7
3
2
.5
5
9
.3
5
5
.5
5
0
.4
5
5
.1
5
5
.1
3
1
4
.8
N
o
n
-d
ir
ec
t
5
4
.5
5
4
.5
5
4
.5
5
4
.5
5
4
.5
5
4
.5
5
4
.5
5
4
.5
A
R
T
1
2
1
.3
5
1
5
.4
2
6
3
.8
3
7
3
3
1
8
.4
2
1
6
.6
P
ro
p
h
yl
ax
is
3
.8
8
.7
7
.6
8
.3
1
0
.8
8
.9
4
.9
M
e
d
ic
at
io
n
s
1
2
.5
1
0
.8
1
6
.7
1
3
.7
1
8
.4
1
1
.5
1
5
.1
2
6
.6
La
b
o
ra
to
ry
6
9
.6
1
2
7
.4
1
5
5
.2
1
5
6
.1
1
0
2
.4
1
4
9
.6
1
4
0
.8
1
6
3
.8
P
e
e
r-
e
d
u
ca
to
rs
*
C
o
n
d
o
m
s
9
.2
4
.3
6
.8
2
.9
2
1
.5
5
.8
9
.3
5
.3
O
ve
rh
e
ad
3
1
1
.1
3
1
1
.1
3
1
1
.1
3
1
1
.1
3
1
1
.1
3
1
1
.1
3
1
1
.1
3
1
1
.1
M
e
an
/p
at
ie
n
t
5
0
4
.6
5
4
4
.8
7
3
3
.5
1
1
1
6
.8
8
3
0
.4
9
7
1
.3
9
1
3
1
0
9
8
.0
8
R
an
g
e
4
6
8
.2
–
5
7
1
.1
5
0
0
.6
–
5
9
1
.7
7
0
6
.9
–
7
7
5
.2
6
7
5
.1
–
2
0
4
5
.5
6
8
1
.8
–
1
1
9
6
.7
6
9
4
.8
–
1
7
7
6
.1
M
e
an
/v
is
it
5
6
.7
7
0
6
8
9
9
.4
7
6
.7
7
8
.3
8
0
.6
O
SW
d
e
n
o
te
s
o
cc
as
io
n
al
se
x
w
o
rk
e
r;
an
d
FT
SW
d
e
n
o
te
s
fu
ll
ti
m
e
se
x
w
o
rk
e
r
*I
n
ch
ar
g
e
o
f
p
at
ie
n
ts
se
e
ki
n
g
,
e
d
u
ca
ti
o
n
/b
e
h
av
io
u
r
se
ss
io
n
,
p
at
ie
n
t
tr
ac
ki
n
g
an
d
in
vo
lv
e
d
in
A
R
T
ad
h
e
re
n
ce
su
p
p
o
rt
al
o
n
g
w
it
h
th
e
p
sy
ch
o
lo
g
is
t,
p
h
ar
m
ac
y
n
u
rs
e
an
d
p
h
ys
ic
ia
n
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
0
1
0
7
.t
0
0
3
Cost of Providing ART for Female Sex Workers
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e100107
ranged between US$468-571, largely made up of high overhead
costs. The high proportion of personnel costs (20%) in this group
reflects the psychological support offered with every serology test.
We found discrepancies (23%) between our two costing
methods. This is not unusual as the literature reports 15–25% as
a modest discrepancy [38]. The large discrepancy in personnel
costs may mean the clinic was not working at full capacity (related
to a reduced research funding at the time), whereas discrepancies
in other cost categories may be due to heterogeneity within the
cohort and our samples. As our main output measure was the
mean cost per patient year, a larger sample may be required to
reduce the uncertainty in our estimates, especially for ART costs
where the bottom-up mean ART cost was 53% greater than the
top-down estimate. The smaller discordance in laboratory costs
was probably due to the lower rates of viral load testing recorded
in our patient-specific samples than in our whole cohort.
Our sensitivity analysis showed that neither the discount rate
used nor the uncertainty in consumables had any real impact on
average costs. However, swapping existing ART regimens to ones
containing tenofovir increased the mean cost per patient year by
13% for d4T regimens and 28% for AZT regimens. This has
important policy implications, because as evidence mounts to
support the use of tenofovir as a first line agent [35,39] its higher
cost may hamper the achievement of universal coverage. The
increasing number of patients on more costly second-line therapies
may also hinder universal coverage [40,41]. It is therefore essential
that low-income countries begin to explore ways to acquire these
more expensive drugs at lower costs.
The clinic’s research activities required both a greater number
of staff and a higher number of laboratory investigations being
performed. Decreasing the number of laboratory tests in line with
National Guidelines resulted in a 6% reduction in average cost,
whereas when all research costs were removed there was a 16%
reduction in average patient cost. When we combine this with a
reduction in salaries to national levels then a 29% reduction in the
yearly cost per patient was achieved, giving an average cost of
US$780 per patient year on ART. This highlights the heavy
research costs incurred by the Yerelon clinic and suggests that
integration into the public health system might be achieved at
reasonable cost. Though these results are promising, they should
be interpreted with caution. A reduction in resources used could
result in a concurrent reduction in intervention effectiveness,
possibly through lower adherence or higher loss to follow up and
treatment failure from having a reduced diagnostic schedule and
lower paid, less qualified staff.
Our cost estimates vary somewhat from the existing literature
on HIV treatment costs; however, all comparative literature
(Table 5) has examined costs of HIV treatment in the general adult
population and not FSWs. Existing studies from Africa have found
a large variation in costs with most being lower than ours but
many having higher ART costs. The difference between our
estimated annual cost and these published estimates can probably
be explained by two main factors. Firstly, the Yerelon clinic
incurred large research-related personnel and laboratory costs
described above. When these elevated costs are adjusted, the costs
from our analysis reduce below many of the estimates included in
Table 5. Secondly, the intervention provided at the clinic is both
preventative and therapeutic, whereas the studies in Table 5
focused solely on HIV treatment.
There are several limitations to our study. A provider
perspective can underestimate total economic costs. In addition,
we chose not to separate prevention and treatment cost as the aim
of the clinic was to provide both services in a combined package.
Start-up costs were also not as they were not available. These
could be significant when integration into the public system
occurs. Also, though the major research costs were removed in our
sensitivity analysis, it was difficult to truly separate out all resources
used for research purposes. Lastly, our patient-specific sample was
small, representing only 13% of our cohort – this resulted in a few
patients skewing the results for specific patient groups. However,
though the sample is small, it does allow to examine cost
differences between different exposure levels.
In this current economic climate, we must focus our limited
resources in innovative ways. The pivotal role of FSW in the
Table 4. Results of sensitivity analysis on mean cost of care per woman treated in 2012 US$.
ART women Non-ART women All women
Base case 1098 882 1014
Costs of consumables
210% 1094 877 1010
220% 1090 873 1005
Remove research costs 928 712 845
Assume national wages for staff 1040 824 956
National guidelines for laboratory testing 1029 812 945
Best case (combine 3 above) 781 564 697
Remove research cost and increase of 500 women
Use AZT instead of d4t 1107 882 1019
Use TDF instead of d4T 1236 882 1098
Use TDF instead of d4t and AZT 1407 882 1203
Discount rate (3% in base case)
1% 1095 879 1012
2% 1097 881 1013
10% 1104 887 1020
doi:10.1371/journal.pone.0100107.t004
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transmission of HIV in many settings demands a targeted
programme of combined prevention and treatment for these
women. Such a dedicated service, as the Yerelon clinic, can
produce good results in terms of behaviour change, virological
suppression and decreases in HIV incidence and prevalence, at
costs which does not differ from those of routine HIV care clinics
for the general population [23,24]. Our study is the first to report
on the costs of such a combined intervention for FSWs. Even at a
time of severe budgetary constraints, investing in ‘‘difficult to
reach’’, high-risk groups should be a priority in countries with
modest HIV prevalence in the general population (mainly West/
North Africa and South-East Asia regions), because of the large
public health gains in controlling the HIV dynamics. In addition,
our study shows that the cost of this combined approach is
comparable to other treatment-only interventions in the general
population. This, coupled with the good biological and behav-
ioural results seen in our cohort, suggests that this intervention
may be cost-effective. The cost of this important intervention
should, therefore, not be a prohibitive factor in scaling it up across
Burkina Faso and elsewhere with the average costs likely to
decrease as this is done [42,43]. Of priority now, is combining
impact evaluation to our cost data to determine the cost-
effectiveness of such an intervention.
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